{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:12:22Z","timestamp":1762542742830,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T00:00:00Z","timestamp":1505779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T00:00:00Z","timestamp":1505779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The purpose of this study was to investigate the anatomical and functional outcomes of the two-stage treatment of severe retinopathy of prematurity (ROP) using laser photocoagulation and intravitreal ranibizumab injection. The medical records of 53 eyes of 28 infants treated by conventional laser photocoagulation with deferred intravitreal 0.25\u2009mg\/0.025\u2009mL ranibizumab injection were analysed. All patients had at least 11 months of follow-up. In the analysed group, the mean gestational age at birth was 25\u2009weeks and mean birthweight was 790\u2009g. The mean time of laser photocoagulation was 34\u2009weeks of postmenstrual age (PMA). Ranibizumab injection was performed on average at 37\u2009weeks of PMA. The mean time between interventions was 19 days. Retinal detachment occurred in 12 eyes (22.6%), in three children bilaterally. Visual responses were obtained in 23 of 28 treated children. Our results indicate that ranibizumab injection can be taken into consideration in the selected cases of laser photocoagulation failure. The unsatisfactory results of this study elicited a change in the ROP treatment protocol in our medical centre. The study gives an insight into anatomical and functional outcomes of ROP treatment in the Central and Eastern European population.<\/jats:p>","DOI":"10.1038\/s41598-017-12264-z","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T13:29:10Z","timestamp":1505309350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment"],"prefix":"10.1038","volume":"7","author":[{"given":"Anna","family":"Gotz-Wi\u0119ckowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Chmielarz-Czarnoci\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8465-1753","authenticated-orcid":false,"given":"Marta","family":"Pawlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Gadzinowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Mazela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,19]]},"reference":[{"key":"12264_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","volume":"84","author":"C Gilbert","year":"2008","unstructured":"Gilbert, C. Retinopathy of prematurity: A global perspective of the epidemics, population of babies at risk and implications for control. Early Hum. Dev. \n                           84, 77\u201382 (2008).","journal-title":"Early Hum. Dev."},{"key":"12264_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner, H. A., Kennedy, K. A. & Chuang, A. Z. & BEAT-ROP Cooperative Group. Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity. N. Engl. J. Med. \n                           364, 603\u2013615 (2011).","journal-title":"N. Engl. J. Med."},{"key":"12264_CR3","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","volume":"100","author":"A-L H\u00e5rd","year":"2011","unstructured":"H\u00e5rd, A.-L. & Hellstr\u00f6m, A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review. Acta Paediatr. \n                           100, 1523\u20137 (2011).","journal-title":"Acta Paediatr."},{"key":"12264_CR4","doi-asserted-by":"crossref","unstructured":"Morin, J. et al. Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity. Pediatrics \n                           137, (2016).","DOI":"10.1542\/peds.2015-3218"},{"key":"12264_CR5","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1097\/IAE.0b013e3181cb6151","volume":"30","author":"KA Drenser","year":"2010","unstructured":"Drenser, K. A., Trese, M. T. & Capone, A. Aggressive posterior retinopathy of prematurity. Retina \n                           30, S37\u201340 (2010).","journal-title":"Retina"},{"key":"12264_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1067\/mpa.2000.107904","volume":"4","author":"X Katz","year":"2000","unstructured":"Katz, X., Kychenthal, A. & Dorta, P. Zone I retinopathy of prematurity. J. Am. Assoc. Pediatr. Ophthalmol. Strabismus \n                           4, 373\u2013376 (2000).","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"12264_CR7","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/01.iae.0000244285.79004.e6","volume":"26","author":"A Kychenthal","year":"2006","unstructured":"Kychenthal, A., Dorta, P. & Katz, X. Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina \n                           26, S11\u2013S15 (2006).","journal-title":"Retina"},{"key":"12264_CR8","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1097\/IAE.0000000000000604","volume":"35","author":"A Vinekar","year":"2015","unstructured":"Vinekar, A. et al. Comparing the outcome of single versus multiple session laser photoablation of flat neovascularization in zone 1 aggressive posterior retinopathy of prematurity: A Prospective Randomized Study. Retina \n                           35, 2130\u20132136 (2015).","journal-title":"Retina"},{"key":"12264_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","volume":"35","author":"RK Wong","year":"2015","unstructured":"Wong, R. K., Hubschman, S. & Tsui, I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina \n                           35, 675\u2013680 (2015).","journal-title":"Retina"},{"key":"12264_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/IAE.0b013e318296e26d","volume":"34","author":"J Kim","year":"2014","unstructured":"Kim, J., Kim, S. J., Chang, Y. S. & Park, W. S. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Retina \n                           34, 77\u201382 (2014).","journal-title":"Retina"},{"key":"12264_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3109\/02713683.2014.941070","volume":"40","author":"B Araz-Ersan","year":"2015","unstructured":"Araz-Ersan, B. et al. Preliminary Anatomical and Neurodevelopmental Outcomes of Intravitreal Bevacizumab As Adjunctive Treatment for Retinopathy of Prematurity. Curr. Eye Res. \n                           40, 585\u2013591 (2015).","journal-title":"Curr. Eye Res."},{"key":"12264_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000338623","volume":"3","author":"A Mota","year":"2012","unstructured":"Mota, A. et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep. Ophthalmol. \n                           3, 136\u201341 (2012).","journal-title":"Case Rep. Ophthalmol."},{"key":"12264_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","volume":"155","author":"W-C Wu","year":"2013","unstructured":"Wu, W.-C. et al. An Updated Study of the Use of Bevacizumab in the Treatment of Patients with Prethreshold Retinopathy of Prematurity in Taiwan. Am. J. Ophthalmol. \n                           155, 150\u2013158.e1 (2013).","journal-title":"Am. J. Ophthalmol."},{"key":"12264_CR14","unstructured":"The guidelines of the National Specialist Team in Paediatrics and School Medicine of 15 December 1992 on common preventive medical examinations of newborns, infants and children up to 2\u2009years of age. Pediatr. Pol. 68, 48\u201350 (1993)."},{"key":"12264_CR15","doi-asserted-by":"crossref","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch. Ophthalmol. (Chicago, Ill. 1960) \n                           121, 1684\u201394 (2003).","DOI":"10.1001\/archopht.121.12.1684"},{"key":"12264_CR16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1755-3768.2011.02351.x","volume":"91","author":"U Spandau","year":"2013","unstructured":"Spandau, U. et al. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol. \n                           91, 170\u2013175 (2013).","journal-title":"Acta Ophthalmol."},{"key":"12264_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","volume":"35","author":"S-N Chen","year":"2015","unstructured":"Chen, S.-N. et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina \n                           35, 667\u201374 (2015).","journal-title":"Retina"},{"key":"12264_CR18","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri, S. J. et al. Pharmacokinetics of Intravitreal Ranibizumab (Lucentis). Ophthalmology \n                           114, 2179\u20132182 (2007).","journal-title":"Ophthalmology"},{"key":"12264_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","volume":"14","author":"JC Law","year":"2010","unstructured":"Law, J. C., Recchia, F. M., Morrison, D. G., Donahue, S. P. & Estes, R. L. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J. Am. Assoc. Pediatr. Ophthalmol. Strabismus \n                           14, 6\u201310 (2010).","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"12264_CR20","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00417-010-1430-x","volume":"248","author":"H Nazari","year":"2010","unstructured":"Nazari, H., Modarres, M., Parvaresh, M. M. & Ghasemi Falavarjani, K. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. \n                           248, 1713\u20131718 (2010).","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"12264_CR21","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","volume":"246","author":"S Honda","year":"2008","unstructured":"Honda, S., Hirabayashi, H., Tsukahara, Y. & Negi, A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. \n                           246, 1061\u20131063 (2008).","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"12264_CR22","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.3928\/01913913-20100901-04","volume":"47","author":"N Erol","year":"2010","unstructured":"Erol, N., G\u00fcrsoy, H., Sahin, A. & Basmak, H. Intravitreal Bevacizumab Following Laser Therapy for Severe Retinopathy of Prematurity. J. Pediatr. Ophthalmol. Strabismus \n                           47, e1\u20134 (2010).","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"12264_CR23","unstructured":"Gotz-Wi\u0119ckowska, A. The impact of selected risk factors on incidence, course and results of treatment of retinopathy of prematurity. (Pozna\u0144: Wydaw. Nauk. AM im. Karola Marcinkowskiego w Poznaniu, 2007)."},{"key":"12264_CR24","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","volume":"91","author":"R Hoerster","year":"2013","unstructured":"Hoerster, R. et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. \n                           91, e74\u2013e75 (2013).","journal-title":"Acta Ophthalmol."},{"key":"12264_CR25","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1097\/IAE.0000000000000535","volume":"35","author":"YR Hong","year":"2015","unstructured":"Hong, Y. R. et al. Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection. Retina \n                           35, 1772\u20137 (2015).","journal-title":"Retina"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12264-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12264-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12264-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T11:08:38Z","timestamp":1671793718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12264-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,19]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["12264"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-12264-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2017,9,19]]},"assertion":[{"value":"15 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11894"}}